Cel therapy
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Excerpt from the Press Release: SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the…
Read More
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy metabolism by inhibiting aerobic glycolysis Excerpt from the Press Release: BERWYN, PA, Feb. 01, 2024 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company…
Read More
Excerpt from the Press Release: SAN FRANCISCO, USA – February 1, 2024 – Mahana Therapeutics, a leading provider of digital therapeutics, announced today that positive results from a large US-based Pilot Clinical Trial, have been accepted for presentation at the upcoming American Audiology Society (AAS) Scientific and Technology Meeting, on February 15-17, 2024 in Scottsdale,…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Xcell Biosciences, Inc. (Xcellbio), a platform technology company focused on cell and gene therapy applications, today announced a collaboration with ElevateBio, LLC (ElevateBio), through which the companies aim to explore novel approaches to improving therapeutic potency of cell and gene therapies. As part of this collaboration, ElevateBio becomes…
Read More
Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene RCT1100 is the first clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced the first patient dosed with engineered B cell therapy ISP-001 in a Phase 1 trial in MPS I, at M…
Read More
— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 — — Caribou plans to initiate Phase…
Read More
Casgevy the 1st medicine licensed using the gene editing tool CRISPR Excerpt from the Press Release: Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the disease in the U.K. In a statement on Thursday, the Medicines…
Read More
Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time Rejuva platform and genetic medicines offer potential for reversal of Type 2 Diabetes with a single point-in-time local administration of durable GLP-1-based genetic medicines Excerpt from the Press Release:…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, today announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease (MMVD), at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 16-20, 2023, in Los Angeles, California. RJB-01, expresses…
Read More